Grace Therapeutics (GRCE) Stock Price, News & Analysis

Company Overview

Grace Therapeutics is a development-stage biopharmaceutical company focused on overcoming the limitations of traditional drug delivery through its proprietary transdermal platform. The company is advancing novel therapies designed to deliver large-molecule biologics and vaccines across the skin barrier, with the goal of improving patient compliance, enhancing therapeutic efficacy and reducing dosing frequency compared with conventional injectable approaches.

The company’s lead candidates are currently in preclinical development for dermatological and immunological conditions. Grace Therapeutics’ platform is engineered to maintain the stability of sensitive biomolecules, enable controlled release and minimize the discomfort associated with conventional injections. The company collaborates with academic and industry partners to refine its microneedle and reservoir technologies and to expand its research pipeline.

Based in Cambridge, Massachusetts, Grace Therapeutics serves a global market for next-generation drug delivery solutions. The company’s management team brings together experienced professionals with backgrounds in biotechnology research, clinical development and commercial operations. As a Nasdaq-listed entity under the ticker GRCE, Grace Therapeutics is building its manufacturing capabilities, advancing its pipeline and pursuing strategic partnerships to support long-term growth.

Key Stats

• Today's Range: $3.24 to $3.40
• 50-Day Range: $2.60 to $3.44
• 52-Week Range: $1.75 to $4.97
• Volume: 36,929 shs
• Average Volume: 62,712 shs
• Market Capitalization: $46.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

Grace Therapeutics Stock Analysis - MarketRank™

Grace Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 547th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Grace Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Grace Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Grace Therapeutics are expected to grow in the coming year, from ($1.06) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Grace Therapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Grace Therapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Grace Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GRCE.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Grace Therapeutics does not currently pay a dividend.

Dividend Growth

Grace Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for GRCE.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for GRCE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Grace Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.51% of the stock of Grace Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 6.08% of the stock of Grace Therapeutics is held by institutions.

GRCE Stock Analysis - Frequently Asked Questions

How have GRCE shares performed this year?

Grace Therapeutics' stock was trading at $3.74 at the beginning of 2025. Since then, GRCE shares have decreased by 10.2% and is now trading at $3.36.

How were Grace Therapeutics' earnings last quarter?

Grace Therapeutics, Inc. (NASDAQ:GRCE) released its quarterly earnings results on Friday, June, 20th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.02.

Who are Grace Therapeutics' major shareholders?

Top institutional shareholders of Grace Therapeutics include Palumbo Wealth Management LLC (0.35%).

How do I buy shares of Grace Therapeutics?

Shares of GRCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 6/20/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GRCE
• Previous Symbol: NASDAQ:GRCE
• CIK: 1444192
• Web: www.acastipharma.com
• Phone: 818-839-4378
• Fax: 45-0687-2272
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Grace Therapeutics: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +257.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -19.45%
• Return on Assets: -16.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.77
• Quick Ratio: 11.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.86 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 13,830,000
• Free Float: 11,961,000
• Market Cap: $46.47 million
• Optionable: N/A
• Beta: 0.92